Melanotan-1 · Research brief

Is Afamelanotide the Same as Melanotan-1? (Mechanism)

Real Peptides Research TeamEditorial

Updated April 10, 20268 min read

60 WORDS

Short answer

Research published in the Journal of Clinical Investigation found that afamelanotide (NDP-α-MSH) activated melanocortin-1 receptors with 1,000 times greater potency than endogenous α-MSH. Establishing it as the first synthetic melanocortin receptor agonist to receive full regulatory approval. That's not just a minor improvement; it's a mechanism shift that turned an experimental tanning peptide into a life-changing treatment for patients with…

Key takeaways

Afamelanotide and Melanotan-1 are the same 13-amino-acid peptide (NDP-α-MSH), but afamelanotide is the pharmaceutical-grade formulation approved by the FDA and EMA.
The peptide activates melanocortin-1 receptors on melanocytes, triggering eumelanin synthesis. The mechanism is identical whether the source is labelled Melanotan-1 or afamelanotide.
Afamelanotide is delivered as a 16mg subcutaneous implant that maintains therapeutic plasma levels for 60 days, while Melanotan-1 was typically injected daily as a reconstituted powder.
Only afamelanotide is legally prescribed for erythropoietic protoporphyria. Melanotan-1 remains an unregulated research peptide without FDA approval for any indication.
The Phase III CUV029 trial demonstrated a 69.4-minute increase in pain-free sunlight exposure per day for EPP patients using afamelanotide implants versus placebo.
Pharmaceutical-grade synthesis under cGMP standards distinguishes afamelanotide from research-grade Melanotan-1. Batch-level sterility, potency, and purity are verified for every clinical implant.

Our team has worked with research facilities exploring melanocortin pathways for years. The confusion around whether afamelanotide is the same as Melanotan-1 isn't just semantic. It reflects a broader misunderstanding about how peptide research compounds evolve into pharmaceutical-grade therapies.

Is afamelanotide the same as Melanotan-1?

Yes. Afamelanotide and Melanotan-1 are the same peptide molecule (NDP-α-MSH, [Nle4,D-Phe7]-α-MSH), but afamelanotide is the pharmaceutical-grade formulation approved by the FDA and EMA for clinical use. Melanotan-1 was the original research designation; afamelanotide is the branded name for the drug product manufactured under cGMP standards. Both activate melanocortin-1 receptors to stimulate eumelanin production, but only afamelanotide is legally prescribed for erythropoietic protoporphyria.

The distinction matters more than most people realise. Melanotan-1 circulated in research labs and grey-market channels for decades before pharmaceutical development began. Afamelanotide didn't just rename the peptide. It standardised the synthesis pathway, validated the subcutaneous implant delivery system, and established clinical dosing protocols through Phase III trials. This article covers the molecular relationship between afamelanotide and Melanotan-1, the regulatory evolution from research peptide to approved orphan drug, and what the mechanism reveals about melanocortin receptor biology.

The Molecular Identity: Why Afamelanotide and Melanotan-1 Are Structurally Identical

Afamelanotide is Melanotan-1. The peptide sequence is [Nle4,D-Phe7]-α-MSH, a 13-amino-acid analogue of alpha-melanocyte-stimulating hormone with two critical modifications: norleucine substituted at position 4 (increasing oxidative stability) and D-phenylalanine at position 7 (increasing resistance to enzymatic degradation). These changes extend the peptide's half-life from minutes (endogenous α-MSH) to approximately 33 minutes after subcutaneous administration.

The name 'Melanotan-1' originated in the late 1980s when researchers at the University of Arizona synthesised a series of melanocortin receptor agonists to study photoprotection. Melanotan-1 and Melanotan-2 (a cyclic variant with broader receptor binding) were the most stable candidates. Melanotan-1 showed selective binding to MC1R (melanocortin-1 receptor) on melanocytes, triggering eumelanin synthesis without the appetite suppression or erectile effects associated with Melanotan-2's MC3R and MC4R activity.

When pharmaceutical development began in the early 2000s, the peptide was rebranded as afamelanotide to meet regulatory nomenclature standards and distinguish the clinical-grade product from research-grade Melanotan-1. The active molecule did not change. Only the manufacturing standards, formulation method (subcutaneous implant vs lyophilised powder), and regulatory oversight. Both terms refer to the same 13-amino-acid sequence, but 'afamelanotide' signals pharmaceutical-grade synthesis, sterility testing, and batch-to-batch potency validation.

The Regulatory Evolution: From Research Peptide to FDA-Approved Orphan Drug

Afamelanotide received orphan drug designation from the FDA in 2008 and full approval (as Scenesse) in 2019 for erythropoietic protoporphyria (EPP), a rare disorder affecting approximately 5,000–10,000 patients worldwide. EPP causes severe phototoxicity. Exposure to visible light triggers oxygen radical formation in red blood cells, leading to acute burning pain, oedema, and skin damage. Patients with EPP often avoid sunlight entirely, with some spending years indoors.

The Phase III trial (CUV029) published in JAMA Dermatology demonstrated that afamelanotide implants increased patients' pain-free sunlight exposure by 69.4 minutes per day compared to placebo. A clinically meaningful improvement for a population with zero alternative treatments. The implant delivers 16mg of afamelanotide over 60 days via a subcutaneous rod inserted in the abdominal wall, maintaining therapeutic plasma levels without daily injections.

Melanotan-1, by contrast, never underwent formal FDA review because it remained a research compound distributed through academic channels and grey-market suppliers. The peptide's tanning effects attracted non-medical interest, but without clinical trial data, dosing protocols, or manufacturing oversight, it stayed in regulatory limbo. The pharmaceutical evolution required more than just branding. It required controlled implant formulation, multi-year safety data, and proof of efficacy in a defined patient population. Afamelanotide's approval didn't validate recreational tanning; it validated a life-altering intervention for a specific rare disease.

Is Afamelanotide the Same as Melanotan-1?: [Comparison]

Before reviewing the distinctions, understand this: the peptide sequence is identical. The differences lie in manufacturing, delivery, and regulatory status.

Feature	Melanotan-1 (Research)	Afamelanotide (Pharmaceutical)	Bottom Line
Peptide sequence	[Nle4,D-Phe7]-α-MSH (13 amino acids)	[Nle4,D-Phe7]-α-MSH (13 amino acids)	Molecularly identical. Same active compound
Regulatory status	Unregulated research peptide	FDA/EMA-approved orphan drug (Scenesse)	Only afamelanotide is legally prescribed
Delivery method	Subcutaneous injection (lyophilised powder reconstituted)	Subcutaneous implant (16mg sustained-release rod)	Implant maintains plasma levels for 60 days
Clinical indication	None (used experimentally for tanning)	Erythropoietic protoporphyria (EPP) only	Afamelanotide is prescribed for a specific rare disease
Manufacturing oversight	Variable (academic or grey-market sourcing)	cGMP facilities with FDA batch oversight	Pharmaceutical-grade guarantees potency and sterility
Dosing protocol	Inconsistent (typically 0.5–2mg daily injections)	16mg implant every 60 days (clinical trial validated)	Afamelanotide dosing is standardised from Phase III data

What If: Afamelanotide and Melanotan-1 Scenarios

What if I've used Melanotan-1 recreationally — does that mean I've used afamelanotide?

You've used the same active peptide, but not the same product. Research-grade Melanotan-1 sourced through grey-market suppliers lacks the manufacturing oversight, sterility testing, and potency validation required for pharmaceutical-grade afamelanotide. The amino-acid sequence is identical, but the impurity profile, bacterial endotoxin levels, and actual peptide content per vial can vary significantly. Clinical afamelanotide implants undergo FDA batch review; research peptides do not.

What if my doctor prescribes afamelanotide off-label for tanning — is that the same as using Melanotan-1?

Afamelanotide is FDA-approved exclusively for erythropoietic protoporphyria. Off-label prescribing for cosmetic tanning is not supported by regulatory approval or clinical trial data. While the melanocortin-1 receptor mechanism triggers eumelanin synthesis regardless of indication, insurance will not cover off-label use, and the implant delivery system is designed for sustained melanocortin activation in photoprotection, not recreational tanning. Prescribing afamelanotide for tanning does not make the practice equivalent to historical Melanotan-1 use. The regulatory and ethical frameworks are entirely different.

What if research facilities still refer to the peptide as Melanotan-1 — does that mean it's not afamelanotide?

Nomenclature depends on context. Academic publications and basic research labs often use 'Melanotan-1' or 'NDP-α-MSH' when discussing the peptide's mechanism or receptor pharmacology, while clinical and pharmaceutical contexts use 'afamelanotide' to designate the drug product. Both terms describe the same molecule, but the naming convention signals whether the discussion involves research-grade peptides or pharmaceutical-grade implants. If a study references 'Melanotan-1', check whether the peptide was sourced from a cGMP facility or synthesised in-house. That distinction matters more than the name.

The Unvarnished Truth About Afamelanotide and Melanotan-1

Here's the honest answer: calling afamelanotide 'just another name for Melanotan-1' is technically correct but practically misleading. The peptide is identical, but everything surrounding it. Manufacturing, delivery, clinical validation, and legal status. Is fundamentally different. Research-grade Melanotan-1 was an experimental tanning peptide with inconsistent sourcing and zero regulatory oversight. Afamelanotide is a life-changing orphan drug for patients with a debilitating genetic disorder, backed by Phase III efficacy data and manufactured under the same standards as any FDA-approved biologic. The molecular biology is the same; the contexts are not.

The Mechanism That Defines Both: Melanocortin-1 Receptor Activation

Whether labelled afamelanotide or Melanotan-1, the peptide functions identically at the cellular level. NDP-α-MSH binds to melanocortin-1 receptors (MC1R) on epidermal melanocytes, activating adenylyl cyclase and increasing intracellular cyclic AMP. Elevated cAMP activates MITF (microphthalmia-associated transcription factor), the master regulator of melanogenesis, which upregulates tyrosinase. The enzyme that converts tyrosine to DOPA, then dopaquinone, then eumelanin.

Eumelanin is the dark, photoprotective pigment responsible for skin tanning. Unlike pheomelanin (the red-yellow pigment in fair-skinned individuals), eumelanin absorbs UV radiation and scavenges reactive oxygen species, reducing DNA damage and lowering the risk of UV-induced mutations. This is why afamelanotide works in EPP. Patients with this disorder produce excess protoporphyrin IX in their red blood cells, which absorbs visible light and generates oxygen radicals. Increasing eumelanin through MC1R activation provides a protective barrier against the wavelengths that trigger phototoxic reactions.

The D-phenylalanine substitution at position 7 slows enzymatic degradation by neprilysin and aminopeptidases, extending the peptide's half-life from the 2–3 minutes typical of endogenous α-MSH to approximately 33 minutes. The norleucine substitution at position 4 prevents oxidation of the methionine residue found in natural α-MSH, further stabilising the molecule in vivo. These modifications don't alter the receptor binding site. They simply allow the peptide to remain active long enough to trigger sustained melanogenesis.

Afamelanotide is the same peptide as Melanotan-1 because both activate MC1R with the same amino-acid sequence. If afamelanotide's clinical reputation seems disconnected from Melanotan-1's grey-market history, it's because the pharmaceutical pathway validated the peptide's mechanism in a medical context, not because the molecule changed. The biology was always there. The regulatory approval formalised it.

Afamelanotide's implant delivery mirrors this biological reality: sustained MC1R activation over 60 days maintains elevated eumelanin synthesis without daily injections. For EPP patients, that continuity is the difference between life indoors and the ability to tolerate daylight. Melanotan-1 required daily reconstitution and injection. Achievable in research settings but impractical for long-term clinical use. The implant solved the compliance problem while preserving the peptide's core mechanism. That innovation, combined with clinical trial validation, is what separates pharmaceutical-grade afamelanotide from research-grade Melanotan-1 in practical terms.

The takeaway: afamelanotide didn't improve on Melanotan-1's pharmacology. It standardised and clinically validated what Melanotan-1 always was. Both are NDP-α-MSH. Both activate MC1R. Both trigger eumelanin synthesis. The difference is that afamelanotide proved it in a controlled trial and earned regulatory approval. Melanotan-1 remained an experimental compound with anecdotal use. Same peptide. Different path.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Questions

Yes — afamelanotide and Melanotan-1 are the same peptide molecule, [Nle4,D-Phe7]-α-MSH, with identical amino-acid sequencing. The difference is nomenclature: ‘Melanotan-1’ was the original research designation, while ‘afamelanotide’ is the pharmaceutical-grade branded name used in clinical settings. Both bind to melanocortin-1 receptors and trigger eumelanin synthesis through the same biological mechanism.

No — while the active peptide is identical, research-grade Melanotan-1 lacks the manufacturing oversight, sterility validation, and batch-level potency testing required for pharmaceutical-grade afamelanotide. Afamelanotide is FDA-approved exclusively for erythropoietic protoporphyria and delivered via a 16mg sustained-release implant. Grey-market Melanotan-1 is unregulated, typically sold as lyophilised powder without clinical dosing protocols, and carries significant quality and safety risks.

Afamelanotide (Melanotan-1) is a linear 13-amino-acid peptide selective for melanocortin-1 receptors, triggering melanogenesis without affecting appetite or sexual function. Melanotan-2 is a cyclic 7-amino-acid analogue with broader receptor binding — it activates MC1R, MC3R, and MC4R, leading to tanning, appetite suppression, and erectile effects. Melanotan-2 is not FDA-approved for any indication, while afamelanotide is approved for EPP.

Pharmaceutical-grade afamelanotide (Scenesse) costs approximately $150,000–$170,000 per year in the United States, covered by insurance for patients with confirmed erythropoietic protoporphyria under orphan drug programs. Research-grade Melanotan-1, sourced through grey-market suppliers, typically costs $50–$150 per vial (10mg), but quality, purity, and sterility are not guaranteed. The price difference reflects regulatory approval, cGMP manufacturing, clinical validation, and implant delivery technology.

Yes — both afamelanotide and Melanotan-1 activate the same melanocortin-1 receptor pathway, so adverse effects are mechanistically identical. The most common side effects in clinical trials were nausea (30–40% of patients), injection site reactions, headache, and darkening of existing nevi (moles). Hyperpigmentation is dose-dependent and reversible upon discontinuation. Serious adverse events, including melanoma risk elevation in predisposed individuals, remain a monitoring consideration for any melanocortin agonist.

Afamelanotide has demonstrated safety in Phase III trials over multiple years in patients with erythropoietic protoporphyria, with the most significant concern being hyperpigmentation and potential melanoma risk in individuals with pre-existing dysplastic nevi or family history of melanoma. Long-term data beyond five years is limited, as the drug received FDA approval in 2019. Patients receiving afamelanotide undergo regular dermatological monitoring to detect any pigmented lesion changes early.

Melanotan-1 remained a research peptide without a pharmaceutical sponsor to fund the clinical trials, manufacturing infrastructure, and regulatory submissions required for FDA approval. Clinuvel Pharmaceuticals developed afamelanotide as a pharmaceutical product, conducted Phase I–III trials, and secured orphan drug designation for erythropoietic protoporphyria. The peptide’s mechanism was always known — the approval process required controlled trials proving efficacy and safety in a defined patient population.

No — afamelanotide is a patented orphan drug with FDA approval, which precludes compounding pharmacies from reproducing it under the Drug Quality and Security Act. Compounding is permitted for drugs in shortage or without commercially available alternatives; afamelanotide does not meet those criteria. Some compounding facilities may offer ‘Melanotan-1’ as a research peptide, but this is not the same as pharmaceutical-grade afamelanotide and is not legal for human therapeutic use.

Yes — afamelanotide (Scenesse) is a prescription-only medication available exclusively through specialty pharmacies and administered by healthcare providers trained in implant insertion. It is prescribed only for patients with confirmed erythropoietic protoporphyria, typically diagnosed via genetic testing for FECH gene mutations and elevated erythrocyte protoporphyrin levels. Off-label prescribing for cosmetic tanning is not FDA-approved and is not covered by insurance.

Hyperpigmentation induced by afamelanotide is reversible — eumelanin levels gradually decline over 3–6 months after discontinuation as melanocytes return to baseline melanogenesis rates. For patients with erythropoietic protoporphyria, stopping afamelanotide means the loss of photoprotection, so the decision to discontinue is typically made in consultation with a dermatologist based on symptom severity and quality-of-life considerations. No withdrawal syndrome or rebound effects have been documented.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA